Alain Huriez
President & General Partner @ AdBio partners
Alain Huriez is a seed investor at AdBio partners focused on Biotechnology and Internet. Alain Huriez - President & General Partner @ AdBio partners
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alain Huriez invests in
Stages Alain Huriez invests in
Countries Alain Huriez invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (50%)
- Internet 1 (13%)
- Health Care 1 (13%)
- Life Science 1 (13%)
Stage
- Seed 4 (50%)
- Venture - Series Unknown 2 (25%)
- Series B 1 (13%)
Country
- France 5 (63%)
- Spain 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | |
Astraveus
|
Designing and building closed, automated, bioprocessing systems for the production of cell and gene therapies. | $18.1M / Seed / Jun 27, 2023 | |
Anoat Therapeutics
|
Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis. | $2.2M / Seed / Jun 19, 2023 | |
|
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $46.5M / Series B / May 03, 2023 | |
Calida Therapeutics
|
Calida Therapeutics operates as a biotechnology company. Calida Therapeutics develops monoclonal antibodies to treat and prevent thrombo-inflammatory disorders. | $2.2M / Seed / Apr 06, 2023 | |
Tridek-One
|
Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and givethem a better life. | $16M / Venture - Series Unknown / Sep 15, 2022 | |
|
ARTHEx Biotech
|
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $5M / Seed / Jul 24, 2020 | |
Wellium
|
Wellium is a medical teleconsultation solution allowing doctors to consult their patients online. | $2.2M / Venture - Series Unknown / Mar 27, 2020 |
Co-Investors
About AdBio partners
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
AdBio partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alain Huriez
President & General Partner
|
|||
Arnaud Foussat
Operating Partner
|
|||
Matthieu Coutet
Managing Partner
|
|||
Francesc Dosrius
Junior Analyst
|
|||
Jeremie Mariau
Operating Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alain Huriez invest in?
Alain Huriez invests primarily in Biotechnology, Internet and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alain Huriez?
Public channels for Alain Huriez include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alain Huriez last invest?
The most recent investment recorded for Alain Huriez closed in Sep 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
